… cytokines or by neutralizing them by using blocking antibodies, have been extensively used
over the past … to develop new therapies, which block inflammatory cytokines only at sites of …

… engineering strategies undertaken to enhance their therapeutic applicability. This review
categorizes representative studies mainly over the past 5 years into three groups based on the …

… Several new drugs have been introduced into clinical IBD therapy in the past few decades
that … blockers (such as ustekinumab and JAK inhibitors) suppressing cytokine signalling are …

… review provides a brief background on the characteristics of cytokines and their history as
clinical therapeutics, … engineering strategies developed for cytokine therapies with a focus on …

… therapeutic landscape, including historical perspectives, molecular characteristics, regulatory
benchmarks, and a therapeutic … peptide receptors and cytokine receptors with endogenous …

… cytokine. We mention the diseases in which IL-6 has been implicated and specify possible
therapeutic targets … Research during the past 20 years has revealed an enormous repertoire …

… past 40 years, cytokines and cytokine receptors have been extensively investigated as either
cancer targets … This Review focuses on cytokines and cytokine receptors rather than on …

… it has become a primary therapeutic target among IL-6 family cytokines. Here, we revisit the
discovery of IL-6; discuss insights regarding the roles of this family of cytokines; and highlight …

… has confirmed its superiority to standard of care therapies. In this manuscript, we explore
the history of CD30 as a tumor marker and as a therapeutic target, both in the laboratory and in …

… The history of cytokine development shows them as soluble factors … review will highlight
the impact of cytokines in various physiological actions, pathophysiological states, therapeutics …